Breaking News
Is Big Pharma Selling Postpartum Depression to New Moms?
Make Men Men Again: Low T Is Now a National Defense Problem
Druski: They're Lying To You About Overnight Success!
$6.27 Diesel Just Hit Harvest. The Grocery Aisle Hasn't Felt It Yet.
Top Tech News
Tesla Model 3 killer charges from 10 to 97% in just 9 minutes
World-first unpowered DNA computer sets speed record
I Power 5 Buildings Off-Grid. Here's How
The US government is pushing hard to get a working nuclear fission reactor into space by late 2028
SpaceX Starmind AI in Space Radiator
China Will Dominate Global Nuclear Energy Through 2035, Analyst Says
These Absolutely Wild-Looking EVs Are Saudi Arabia's First Homegrown Cars
BEYOND THE MOON: NASA plans a nuclear-powered fleet to push DEEPER into space
Big Oil Backs Mazama's $135 Million Bet On Superhot Geothermal
Quantum compass takes flight on Northrop's Lumberjack drone 
Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.